APA (7th ed.) Citation

Nandhini, J., & Karthikeyan, E. Nivolumab (Opdivo) in PD-1 pathway inhibition: Enhancing immune response in recurrent oral squamous cell carcinoma. Elsevier.

Chicago Style (17th ed.) Citation

Nandhini, J., and E. Karthikeyan. Nivolumab (Opdivo) in PD-1 Pathway Inhibition: Enhancing Immune Response in Recurrent Oral Squamous Cell Carcinoma. Elsevier.

MLA (9th ed.) Citation

Nandhini, J., and E. Karthikeyan. Nivolumab (Opdivo) in PD-1 Pathway Inhibition: Enhancing Immune Response in Recurrent Oral Squamous Cell Carcinoma. Elsevier.

Warning: These citations may not always be 100% accurate.